share_log

Genpact Analysts Boost Their Forecasts Following Upbeat Earnings

Genpact Analysts Boost Their Forecasts Following Upbeat Earnings

簡伯特分析師在發佈樂觀業績後提高了他們的預測。
Benzinga ·  08/09 14:02

Genpact Limited (NYSE:G) reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates. Also, the company raised its FY24 EPS guidance above estimates.

簡伯特有限公司(NYSE:G)報告了超出預期的第二季度財務業績,併發布了高於預期的FY24營收指引。此外,公司將FY24每股收益指引上調至高於預期。

Genpact reported quarterly earnings of 79 cents per share which beat the analyst consensus estimate of 72 cents per share. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.14 billion.

Genpact每股收益爲79美分,超出分析師預估的72美分,季度銷售額爲11.8億美元,超出分析師預估的11.4億美元。

"Following another quarter of better-than-expected results and a robust first half performance, we are raising our earnings expectations for the year," said Balkrishan "BK" Kalra, Genpact's President and CEO. "Our second quarter results are a testament to the team's ability to successfully deliver on our '3+1 Execution Framework'. Looking ahead, we will continue to drive execution and lean into innovation, leveraging gen AI and other advanced technologies to deliver superior value for clients and drive productivity for Genpact."

"在取得又一季度超出預期的業績和強勁的上半年表現後,我們提高了今年的收益預期,"Genpact總裁兼首席執行官Balkrishan "BK" Kalra表示:"我們的第二季度業績證明了團隊在成功地實施我們的'3+1執行框架'方面的能力。展望未來,我們將繼續推動執行力,並藉助gen AI和其他先進技術推動創新,爲客戶提供卓越的價值,爲Genpact推動生產力。"

Genpact shares gained 16.3% to trade at $37.67 on Friday.

週五,簡伯特股票上漲16.3%,以37.67美元的價格交易。

These analysts made changes to their price targets on Genpact following earnings announcement.

這些分析師在發佈收益公告後調整了他們對簡伯特的價格目標。

  • Needham analyst Mayank Tandon maintained Genpact with a Buy and raised the price target from $40 to $42.
  • TD Cowen analyst Bryan Bergin maintained Genpact with a Hold and boosted the price target from $35 to $36.
  • Needham分析師Mayank Tandon以買入評級維持簡伯特,並將目標價從40美元上調至42美元。
  • TD Cowen分析師Bryan Bergin以持有評級維持簡伯特,並將目標價從35美元上調至36美元。

Considering buying Genpact stock? Here's what analysts think:

考慮買入簡伯特股票嗎?這是分析師們的看法:

big

Read More:

閱讀更多:

  • Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
  • 吉姆·克萊默:這是一隻能源股,應買入,遠離德康醫療。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論